Durvalumab vs Trastuzumab

## Durvalumab vs Trastuzumab: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Trastuzumab**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

**Trastuzumab**: Anti-HER2 monoclonal antibody inhibiting receptor signaling.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Trastuzumab — 28 days.

## Chemical Properties

**Type**: Durvalumab — Antibody; Trastuzumab — Antibody.